D. E. Shaw & Co., Inc. Beam Therapeutics Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $1.19 Million - $2.11 Million	30,000 New	30,000 $1.43 Million
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $641,200 - $1.29 Million	10,000 New	10,000 $1.29 Million

235

76.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.96B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.